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Objectives
To compare virological outcomes in patients who
switched to a cART including efavirenz (EFV), nevira-
pine (NVP) or abacavir (ABC) with patients who contin-
ued on a first virologically successful boosted protease
inhibitor (PI)-containing cART, and to assess virological
differences between the switch regimens.
Methods
Using the French Hospital Database on HIV (FHDH-
ANRS Co4), 439 antiretroviral (ARV)-naive patients
with undetectable viral load (VL) who switched from a
first boosted PI-containing cART to a combination
including EFV (n=196), NVP (n=123) or ABC (n=120)
were selected. Each patient was matched with 3 patients
who did not change their cART on the basis of sex, age,
CD4 cell count, VL and date of the first cART initiation
and duration of undetectability. Time to virological fail-
ure (VF) was analysed using Kaplan-Meier curves and
Cox models. Potential confounding variables considered
for the analyses were HIV transmission group, at the
date of first PI-cART initiation: NRTI backbone, PI
drug; at the index date: AIDS status, CD4 cell count,
NRTIs background, calendar period, time since inclu-
sion in the database, time since first PI-cART initiation,
time between undetectability and switch. Each variable
associated with VF in the univariate model (p<0.20) was
included in a multivariable model designed to evaluate
the impact of the sole switch first, then the impact of
the switch regimen, on the risk of VF. Each model was
stratified by the matched groups (exposed/matched non-
exposed patients).
Results
12-month probabilities of VF were 3.7% in patients not
switching and 5.7% in patients switching, 3.9%, 7.2% and
9.0% in patients switching to EFV-, NVP- and ABC-
cART, respectively. After adjustment on PI at first
cART, CD4 cell counts and AIDS status at the date of
switch, switch was not associated with VF (crude HR,
1.20; 95%CI,0.81-1.77; adjusted HR (aHR), 1.19; 95%CI,
0.80-1.76, compared to no switch). Patients switching to
ABC-cART had a higher risk of VF (aHR, 1.99; 95%CI,
1.05-3.79) than patients not switching, patients switch-
ing to EFV (aHR, 0.82; 95%CI, 0.41-1.65) or NVP (aHR,
0.96; 95%CI, 0.44-2.07) having similar risk of VF com-
pared to patients not switching.
Conclusions
In previously ARV-naive patients, virologically success-
fully treated with a boosted PI-cART, switch to a
NNRTI-cART, either EFV or NVP, is virologically safe,
while switch to an ABC-cART should not be
recommended.
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